# Inhibikase Therapeutics share price today (Inhibikase Therapeutics, Inc., IKT)

> Inhibikase Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. IKT · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/ikt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.56 (+4.0% in a year)
- Revenue (Dec 2023): $0
- Profit (Dec 2023): −$4.2 M
- ROE: −173%, FY23

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Inhibikase Therapeutics share price today? Inhibikase Therapeutics, Inc.'s share price was $1.56 at the close on 4 November 2026. That is 19.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $3, and at that close it sat 7% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 6 weeks running. Over the last 1 year the share price moved −16% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Inhibikase Therapeutics pay? Inhibikase Therapeutics, Inc. pays no dividend. In the last 11 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Inhibikase Therapeutics on? Inhibikase Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Inhibikase Therapeutics profitable? Inhibikase Therapeutics, Inc. posted a net loss of $4.2 M in the Dec 2023 quarter. The full FY23 year was a loss of $19.0 M. The same quarter a year earlier lost $4.3 M. 11 of the last 11 reported quarters were loss-making. ## How much revenue does Inhibikase Therapeutics make, and is it growing? Inhibikase Therapeutics, Inc. reported $0 of revenue in the Dec 2023 quarter, −100.0% on the same quarter a year earlier. Over 2 years it has grown −71.0% a year on average. The last full year, FY23, came in at $261 K. The last four reported quarters add to $261 K. FY23 revenue was $261 K, +112.2% on the year before. Recent pace: the last four quarters grew +635.3% on average, against −71.0% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every $100 of sales does Inhibikase Therapeutics keep? Inhibikase Therapeutics, Inc.'s sales have fallen to very little: FY23 revenue was $261 K, against $3.1 M in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Inhibikase Therapeutics' profit turning into cash? Inhibikase Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY23 its operations used $18.1 M of cash, against −$19.0 M of profit. After $14.0 K of spending on assets, free cash was −$18.1 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Inhibikase Therapeutics' cash go? Inhibikase Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $257 K on assets over the last 2 years. Averaged over those years that is 49.2% of FY23 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $257 K over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Inhibikase Therapeutics' P/E ratio, and how does it compare with its own history? Inhibikase Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Inhibikase Therapeutics, Inc. at 1,091.8× its FY23 revenue of $261 K. The P/E comes back here once profit turns positive. ## Is the Inhibikase Therapeutics business getting better or worse? Inhibikase Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Inhibikase Therapeutics earn on its capital? Inhibikase Therapeutics, Inc. earned a ROE of −173% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −36%, a number that says nothing useful about the business. ## Does Inhibikase Therapeutics have too much debt? Inhibikase Therapeutics, Inc. has total debt of $38.0 K against shareholder equity of $80.1 M as of Jun 2025, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.00 in FY24. So the returns on this page come from the business, not from borrowed money. ## What is the Inhibikase Therapeutics shareholding pattern? 18.3% of Inhibikase Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 29.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Inhibikase Therapeutics from balance-sheet trouble? For Inhibikase Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Inhibikase Therapeutics rank in its industry? There is no score against its industry: Inhibikase Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Inhibikase Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Inhibikase Therapeutics in size? Inhibikase Therapeutics is the 177th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Ocugen, Inc., SAB Biotherapeutics, Inc. and Fulcrum Therapeutics, Inc. Just below it: Q32 Bio Inc., Bicycle Therapeutics plc and Lineage Cell Therapeutics, Inc. ### Biotechnology companies close in size

1. [Ocugen, Inc.](https://www.sectoralpha.in/us/stocks/ocgn) $297 million
2. [SAB Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/sabs) $289 million
3. [Fulcrum Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fulc) $288 million
4. Inhibikase Therapeutics, Inc. $285 million
5. [Q32 Bio Inc.](https://www.sectoralpha.in/us/stocks/qttb) $267 million
6. [Bicycle Therapeutics plc](https://www.sectoralpha.in/us/stocks/bcyc) $261 million
7. [Lineage Cell Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/lctx) $260 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Matrix Service Company](https://www.sectoralpha.in/us/stocks/mtrx) $270 million · Engineering & Construction
2. [Western New England Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/wneb) $270 million · Banks - Regional
3. Inhibikase Therapeutics, Inc. $269 million
4. [Omega Flex, Inc.](https://www.sectoralpha.in/us/stocks/oflx) $268 million · Specialty Industrial Machinery
5. [Alight, Inc.](https://www.sectoralpha.in/us/stocks/alit) $268 million · Software - Application

## What else do people ask about Inhibikase Therapeutics? ### What were Inhibikase Therapeutics's latest quarterly results? Inhibikase Therapeutics, Inc. reported revenue of $0 and a net loss of $4.2 M for the Dec 2023 quarter. Earnings per share were −$0.68 (as of 4 November 2026). ### What is Inhibikase Therapeutics's market cap? Inhibikase Therapeutics, Inc.'s market capitalisation is $285 M at a stock price of $1.56. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Inhibikase Therapeutics performing? Inhibikase Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Inhibikase Therapeutics's stock price go up? This page does not forecast Inhibikase Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $1.56. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Inhibikase Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Inhibikase Therapeutics a stock worth studying right now? What the numbers show: Inhibikase Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.